Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, aged 18–65 years, BMI ≥30 to <50 kg/m2 or BMI ≥27 to <50 kg/m2 with hypertension and/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss ≥5% and change from baseline in systolic blood pressure. RESULTS: CANA/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference –6.9% [95% CI –8.6 to –5.2]; P < 0.001). CANA/PHEN also provided statistically superior achievement of weight loss ≥5% and reduction in systolic blood pressure compared with PBO. CANA/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components. CONCLUSIONS: CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Canagliflozin/phentermine had statistically superior percent weight loss versus placebo (difference of e6.9%; P < .001)(Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“Canagliflozin/phentermine was generally well tolerated, with a safety profile consistent with that of each drug alone (Appendix 3) (Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“The M. Kokkorakis, M. Chakhtoura, C. Rhayem et al. Pharmacological Reviews 77 (2025) 100002 least-square means percent changes in body weight were e1.9 (SE 0.6) with canagliflozin, e4.1 (SE 0.6) with phentermine, and e7.5 (SE 0.6) with canagliflozin/phentermine, and e0.6 (SE 0.6) with placebo (Fig. 4) (Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“In a nod to this idea, current antiobesity medications in the pipeline include dual agonist and triple agonist agents, drugs that simultaneously target multiple pathways (eg, tirzepatide, which targets GLP-1 receptor agonist and GIP receptor agonist) 43 in an attempt to circumvent these natural redundancies.149 -152”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [150]
In the citing paper
“From the perspective of prospective controlled clinical trials, the placebo-corrected phentermine weight reduction is about 3–8%”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [37]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Quantification of the effect of energy imbalance on bodyweight
Hall, K. D., Sacks, G., Chandramohan, D., Chow, C. C., Wang, Y. C., Gortmaker, S. L., & Swinburn, B. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60812-x · Cited by 1,165
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Research works printed but not linked: 1
- Toubro, 2012, Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes, Diabetologia, 55, S313
Cited by
Items 101–115 of 115
The Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Weight Loss in Obesity
Şirali, S. K., & Öztürk, R. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8135540 · Cited by 1
Yoon, S., Park, M. S., Jin, B. H., Shin, H.-B., Na, J., Huh, W., & Kim, C. O. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2249397 · Cited by 1
Available Pharmacological Methods of Obesity Treatment Worldwide - Drugs Review
Zielińska, W., Wanat, J., Dzikowska, I., Siejka, A., Stefaniak, D., Warunek, A., Gronowicz, G., Homa, W. S., & Chról, M. (2025) · Quality in Sport · doi:10.12775/qs.2025.39.58412 · Cited by 1
Nadeem, S., Rana, M. S., Ahmed, K. S., & Kalra, S. (2021) · PubMed
Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus
Jagasia, S. M., Hendrickson, C. D., & Williams, A. J. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch15
Kumar, M., Abbass, N. J., Russell, M. W., Das, N., Singh, R. P., & Talcott, K. E. (2025) · Eye · doi:10.1038/s41433-025-03818-x
de Oliveira, S. C., Pontes, M. R., Bianchini, L. B., Búrigo, J. H., Michelutti, L. M. D., Schroff, W. L. A., Chaves, A., Schroff, K. J. E., dos Santos, H. B., & Loureiro, T. (2025) · International Journal of Nutrology · doi:10.54448/ijn25s303
Systematic review of clinical outcomes of anorexigenic treatment of obesity
Schroff, K. J. E., dos Santos, H. B., Bianchini, L. B., Búrigo, J. H., Michelutti, L. M. D., Pontes, M. R., Schroff, W. L. A., Chaves, A., Loureiro, T., & de Oliveira, S. C. (2025) · International Journal of Nutrology · doi:10.54448/ijn25s306
Anastasio, C., Donisi, I., Vecchio, V. D., Colloca, A., Mele, L. L., Sardu, C., Marfella, R., BALESTRIERI, M. L., & D’Onofrio, N. (2024) · Figshare · doi:10.6084/m9.figshare.25929059
Роль глифлозинов в терапии синдрома висцерального ожирения.2021.pdf
Doe, J. (2021) · Figshare · doi:10.6084/m9.figshare.14299100
Microbiote intestinal et vitamines B dans l’obésité sévère : le cas de la biotine
Voland, L. (2022) · theses.fr (ABES) · doi:10.70675/3d6ab2f6z3844z4eccz9cbazdd1ace927949
ภาวะน้ำหนักลดจากยายับยั้ง Sodium-glucose co-transporter 2
Rattanachaiwong, S. (2021) · Thai JPEN วารสารโภชนบำบัด
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
Sharata, E. E., Abdel-Samea, A. S., Reda, Y., Abdelnaser, M., Rofaeil, R. R., & Mohyeldin, R. H. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02757-2
Metadata
- Authors
- Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N.
- Affiliations
- Baylor University Medical Center (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Dallas Diabetes Research Center (US)
- Janssen Research & Development, LLC, Spring House, PA
- Janssen Research & Development (United States) (US)
- Janssen (Belgium) (BE)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-03-13
- Volume
- 40
- Issue
- 5
- Pages
- 632-639
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2595578651
- Cited by
- 106
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 17 · 2022: 16 · 2021: 18 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 8
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- canagliflozin, phentermine, combination therapy, weight loss, obesity, overweight, non-diabetic obesity, SGLT2 inhibitors, appetite suppressants, systolic blood pressure, hypertension, dyslipidemia, drug safety and tolerability
- MeSH terms
- Canagliflozin, Adult, Appetite Depressants, Blood Pressure, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Phentermine, Thiophenes, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.